











INVESTOR PRESENTATION JUNE-2025

Wide Range Of:

Nutraceuticals, Cosmetics, Ayurevedic, Veterinary Feed & Home Care Products





Safe Harbour



Influx Healthtech Limited (the Company) has submitted Red Herring Prospectus (RHP) with NSE Limited & ROC Dated June 11, 2025 and have received In-principle Approval from NSE Limited to list on Emerge platform dated May 14, 2025. This Presentation aims to provide for financial, business and ownership information about the company, to potential readers / potential investors. It is crucial to note that certain visuals utilized in this presentation may be only for illustrative purposes only, aiming to convey the broad categories of business, that company is actively engaging with. Further, investment in Securities Market is subject to inherent risks, and readers are advised to read the RHP / offer document before making any investment decision. For details on applicable risks, readers are advised to study heading titled "Risk Factors" provided in Red Herring Prospectus.

This presentation is created by Influx Healthtech Limited (the "Company") solely for informational purposes and does not constitute an offer, recommendation, or invitation to purchase or subscribe to any securities. It shall not be considered as the basis or relied upon in connection with any contract or binding commitment whatsoever. The issuance of securities by the company will only take place through a statutory offering document containing comprehensive information about the company. This presentation is compiled by the company based on information and data deemed reliable, but the company makes no explicit or implied representation or warranty whatsoever. No reliance should be placed on the truth, accuracy, completeness, fairness, and reasonableness of the contents of this presentation. It may not encompass all relevant information, and any liability regarding the contents or omissions of this presentation is explicitly disclaimed.

Certain topics discussed in this presentation may involve statements concerning the Company's market opportunities and business prospects that are forward-looking.

These forward-looking statements are not assurances of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are challenging to predict. Such risks and uncertainties include, but are not restricted to, the performance of the Indian economy and global markets, industry performance, competition, successful strategy implementation, future growth, technological changes, and other factors. The Company assumes no obligation to update any forward-looking information contained in this presentation. Any third-party forward-looking statements and projections included in this presentation are not endorsed by the Company, and the Company is not accountable for such third-party statements and projections.

Executive Summary



Hands-on Promoters With More Than Two Decades Of Experience In The Industry

Established by a seasoned industry expert with 20+ years in nutraceutical, cosmetics, ayurvedic and homecare sectors.

Influx, in business since 2020 - operates as Contract Development and Manufacturing Organization (CDMO), which is a third-party manufacturer.

Proven Manufacturing Prowess Backed By Flexible Capacity And Quality Products:

Three Manufacturing units located in Palghar near Mumbai, Maharashtra and headquarter at Mumbai. Multiple Quality certifications such as GMP Compliant, ISO 22000-2018 and HACCP

KEY INVESTMENT RATIONALE

Long-standing Relationship With Marquee Clients:

Clients include "Power Companies," such as Bling brands private limited, Pursuit of wellness Private limited, Aarkios Health Private Limited, HSHS Nutraceuticals limited, Novus Life Science Private Limited, Bruder Life Science, Etc.

Raw materials are procured from third-party suppliers domestically.

And Now, Unveiling The Next Phase Of Growth:

Going public - will lead to expansion by setting up new manufacturing facility for Nutraceutical Division and new Machineries for Cosmetics and Homecare Division Exploring new Division i.e. Veterinary Food.

Introduction



A PIONEERING CDMO ENTERING THE PUBLIC MARKETS

Influx Healthtech Ltd. is a Contract Development and Manufacturing Organization (CDMO) at the forefront of healthcare innovation. With a proven track record in nutraceuticals, cosmetics, pet care and homecare, we are now poised for an Initial Public Offering (IPO) to fuel our next phase of expansion. Influx offers an unmatched combination of regulatory excellence, R&D capabilities and Robust manufacturing infrastructure.

About us



22+ Years of Legacy in CDMO



3,269+ Products



163 People Team



03 Manufacturing Units



104.85 Cr. (FY25)



19.62% EBIDTA Margin (FY25)

People with Passion & Purpose





Shirin Chandniwala, 40 Years (Promoter & Whole-Time Director)

Over 12 years of experience in the Finance industry.

Expert in financial management, data analysis, and budget oversight.

Integral part of the company since its inception.

Bachelor of Commerce (B.Com) from Hemchandracharya North Gujarat University.

Master of Commerce (M.Com) from Hemchandracharya North Gujarat University.



Dr. Munir Chandniwala, 44 Years (Promoter & Managing Director)

Over 22 years of experience in the industries of Nutraceuticals, Cosmetics, Ayurvedic, and Homecare.

Registered Pharmacist with the Maharashtra State Pharmacy Council.

Post Graduate degree in Management and Business Administration from Atharva School of Business, Mumbai.

Bachelor of Pharmacy from the University of Pune.

Doctor of Philosophy (Ph.D.) in HR from Bharatiya Shiksha Parishad, Uttar Pradesh (2010). PGDM (Business Administration).

M.Phil • Diploma in Nutrition.

The Encyclopedia of Nutraceutical Ingredients, Book by DR. Munir Chandniwala



Abdul Chandniwala, 73 Years (Promoter & Non-executive Director)

Over 20 years of experience in the pharmaceutical industry.

Integral part of Influx.

Diploma of Licentiate of the Court of Examiners of Homeopathic and Biochemic Systems of Medicine from the Court of Examiners of Homeopathic and Biochemic Systems of Medicine, Bombay.

Certificate course in Modern Pharmacology.

People with Passion & Purpose





Vipul Patel (54 Years)
Non – Executive
Independent Director.

Mr. Vipul Patel is a dynamic and result oriented professional with 26 years of experience in the healthcare industry. He has completed his M.D in pathology and has also done his M.B.B.S being a part of Maharashtra medical council.



Ashok Jain (59 Years)

Non-Executive
Independent Director

Mr. Ashok Jain is a member of the Institute of Chartered Accountant of India and being a professional he has an experience of over 30 years in the field of financial management, strategic planning and market analysis. He actively contributes to shaping the company's financial strategies and longterm planning.



Ashish Shah (45 Years)
Chief Financial Officer

He was appointed as Chief Financial Officer of the Company on the Board of Influx Healthtech Limited on May 02, 2024. He has completed Bachelor of Commerce from University of Mumbai in the year 2001.



Atul Shukla (35 Years)

Company Secretary
& Compliance Officer

Mr. Atul Kumar was appointed as the Company Secretary & Compliance Officer of our Company at the meeting of the Board of Directors with effect from April 02, 2024. He is a qualified Company Secretary from the Institute of Company Secretaries of India.



Dr. Munir Chandniwala (Managing Director)
Mrs. Shirin Chandniwala (Whole time Director)
Mr. Abdul Ganee Chandniwaala (Director)

CS & CFO

Mr. Atul Shukla (CS) 06 Years Experience

Mr. Ashish Shah (CFO) 25 Years Experience

Mr. Tushar Belkar 08 Years Experience

Ms. Shraddha Chunekar 17 Years Experience

Ms. Jyoti Rewale 09 Years Experience

COO/ PRODUCTION

Mr. Moiz Palgharwala (COO)

12 Years Experience

Mr. Mangesh Mohite 20 Years Experience

Mr. Mushir Khan 20 Years Experience

Ms. Vrunda Bhokre 20 Years Experience

HR & ADMIN

Ms. Shital Thakure 08 Years Experience

BUSINESS DEVELOPMENT OFFICER

Ms. Rachana Parab 11 Years Experience

Ms. Sneha Jadhav 16 Years Experience

Mr. Prashant Tare 27 Years Experience

PURCHASE

Mr. Tushar Varthe 04 Years Experience


Mr. Pravesh Sankhe 04 Years Experience

Mr. Aditya Patil 08 Years Experience

Ms. Manisha Parmar 08 Years Experience

Company History & Vision (Our Journey)





Immense Product Range



Dietary / Nutritional Supplements

- Tablets
- Capsules,
- Powders
- Liquid Orals
- Softgel, etc.
- Gym / Sports
- Supplements
- Liquid Filled Capsules
- Gummies And Effervescent Tablets
- Protein Bars
- Nutritional Ice Candy

Cosmetics

- Skin & Body Care Products
- Face Mask Products
- Beard Care Products
- Hair Care Products
- Bases And Soaps

Ayurvedic / Herbal

- Tablet
- Capsules
- Powders
- Oils
- Liquid Orals
- External Preparations

Veterinary Feeds

- Tablet
- Powders
- Liquid Orals
- Hygiene Care
- External Preparations
- Kibbles

Home Care

- Liquids
- Powders













Manufacturing Capabilities: Powering The Future



INFLUX HEALTHTECH LTD. IS A TRAILBLAZER IN FORMULATION SCIENCE, CONTINUOUSLY DEVELOPING NEXT-GENERATION SOLUTIONS



Liquid-Fill Technology (Capsule-in-Capsule, Pellets-in-Capsule)



Bi-Layer & Centre Filled Gummies



Diskettes Formulation



Oral Film Strips



Nutritional Gel Innovations



Coating Techniques for Hard Gelatin & Softgel Capsules



Protein Bars (Whey & Vegan)



Popped Protein Snacks



Ready-to-Drink Functional Beverages



Soft Gelatin Single-Dose Twist Capsules for Cosmetics



Instant Oil-Removing Face Serums



Instant Face Lifting Serum



Anhydrous Sunscreen



Dog & Cat Food Formulations (Veg & Non-Veg Kibble)

Patents & Proprietary IP



Nutritional Straw Technology – Enabling precise nutrient delivery via innovative straw format



Dissolvable Pouches – Next gen eco-friendly supplement packaging for enhanced consumer onvenience

and many more in pipeline

Key Clientele: Customer Base & Reach



Influx Healthtech Ltd. serves global clientele, including multinational corporations, fast-growing D2C brands, and specialized healthcare providers. Our diversified client portfolio ensures revenue stability and growth resilience.



Bling Brands Private Limited





Pursuit Of Wellness Private Limited



Bruder Life Sciences







Bigflex Lifescience Private Limited









Revenue Bifurcation : Geography Wise



Particulars	31/03/2025	31/03/2024	31/03/2023
Domestic	10,424.33	9970.93	7603.2
Export	61.03	25.58	2.45
Total	10.485.36	9996.51	7605.65



Financial Overview





Rs. In lakhs, unless otherwise stated


Particulars	Financial year ended March 31, 2025	Financial year ended March 31, 2024	Financial year ended March 31, 2023	
Revenue form Operations	10,485.36	9,996.51	7,605.65	
Total number of customers served (Nos.)	571.00	545.00	490.00	
Foreign currency gain / (loss)	(2.22)	0.07	-	
Exports revenue as% of revenue form operation (%)	0.58%	0.26%	0.03%	
Cost of goods sold as % of revenue from operations (%)	73.17%	75.96%	79.64%	
EBITDA	2,057.14	1,695.56	1,072.34	
EBITDA Margin (%)	19.62%	16.96%	14.10%	
EBIT	1,774.69	1,510.12	978.60	
ROCE(%)	49.17%	65.58%	78.60%	
PAT	1,336.60	1,112.80	719.63	
PAT margin (%)	12.75%	11.13%	9.46%	
ROE (%)	36.98%	48.85%	61.76%	
Net working capital days	53	29	18	
Debt to equity ration (times)	0.01	0.01	0.07	
Fixed asset turnover ration (times)	5.59	7.28	12.02	

Dissecting The Revenues









Particulars	31/03/2025	31/03/2024	31/03/2023		
Nutraceuticals	als 9,403.82 9346		7161.16		
Homecare	6.77	68.26	16.40		
Cosmetics	641.05	300.68	211.94		
Ayurvedic	323.95	193.10	175.33		
Veterinary	109.77	87.81	40.82		
Total	10485.36	9996.51	7605.65		

Regulatory Strength & Quality Assurance







































Certificate of Good Manufacturing Practices (GMP) to manufacture of Ayurveda, Siddha, or Unani Drug GMP Certificate by FDA Maharashtra

Good Manufacturing Practice (GMP) System Certificate by RBS Quality Certification Private Limited in accredited by IAF-UK Limited HACCP (Hazard Analysis & Critical Control Points) Certificate by RBS Quality Certification Private Limited in accredited by IAF-UK Limited

HALAL Certification by RBS Quality Certification Private Limited in accredited by IAF-UK Limited ISO 22000: 2018 Food Safety Management Systems by RBS Quality Certification Private Limited in accredited by IAF-UK Limited Certificate of Registration from






Capacity Utilization - Factory Unit 1 (Nutraceuticals)




Location : Plot No -9, Phase -II, Genesis Industrial Township, Kolgaon, Palghar, Thane, Maharashtra - 401404



Capacity Utilization - Factory Unit 2 (Cosmetics and Ayurvedic)




Location: Plot No -57, Phase -1, Genesis Industrial Township, Kolgaon, Palghar, Thane, Maharashtra - 401404



Capacity Utilization - Factory Unit 3 (Pet Supplement and Homecare)



Location : Plot No -1, Phase -1, Genesis Industrial Township, Kolgaon, Palghar, Thane, Maharashtra - 401404




Client Contribution to Revenue (%)








Key Financials















Key Financials











India's Nutraceutical Market: Poised For Robust Growth



India's Nutraceutical sector, valued at USD 30.37 billion in 2024, is set for rapid growth, projected to reach up to USD 64.83 billion by 2030, solidifying its strong 9.22% contribution to the global market.

MARKET SEGMENT							
BY PRODUCT							
Dietary Supplements: Functional Foods: Functional Beverages:							
Dominated the market with	Held 37.6% revenue share in	Growing at 13.9% CAGR					
over 60% revenue share,	2024, including fortified	(2025–2030), led by					
driven by vitamins (C, D, Bcomplex),	products like probiotics and	energy and sports drinks 1.					
proteins, and herbal extracts	omega-3- enriched foods						

BY INGREDIENTS						
Probiotics:	Herbal/Ayurvedic Products:					
Accounted for 24.66% revenue share in	Contributed 30% of the supplements market, leveraging					
2024 due to digestive health benefits	India's traditional medicine heritage					

India's Nutraceutical Market: Poised For Robust Growth



KEY GROWTH DRIVERS

Over 77 million diabetes patients and 200 million people at risk of cardiovascular diseases are driving demand for preventive solutions. Non-communicable diseases (NCDs) account for 67.6% of deaths in India.

RISING CHRONIC DISEASES

India's elderly population (60+ years) is expected to grow from 153 million in 2023 to 347 million by 2050, increasing demand for age-related health products.

AGING POPULATION

Post-COVID-19, immunity-boosting products surged, with 640 million Indians using basic nutraceuticals during the pandemic

PREVENTIVE HEALTHCARE SHIFT

Urban disposable income reached Rs. 214,000 in FY2023–24, fueling health-conscious Spending

FUTURE OUTLOOK

E-commerce Expansion: Online platforms are expected to dominate sales, especially in tier-II/III cities.

Herbal and Personalized Nutrition: Demand for Ayurvedic ingredients (e.g.,ashwagandha, turmeric) and tailored supplements will rise.

Global Hub Potential: India's 52 agro-climatic zones and contract manufacturing

Well-defined Competitive Strengths



Divesified Product Range	Extensive contract manufacturing expertise across multi-nutritional tablets, dietary supplements, Ayurvedic products, oral dispersible films, gummy candies, ice candies, and other innovative wellness solutions.				
Diverse Clientele	Broad industry presence across cosmetics, pharmaceuticals, and homecare, providing a strategic advantage by reducing reliance on any single sector and enhancing financial stability.				
Formulation Development Department	Influx Healthtech Ltd. excels in contract manufacturing for nutraceuticals, cosmetics, Ayurvedic products, homecare and veterinary formulations, driven by an innovative Formulation Development Department for market-ready solutions.				
Stringent Quality Assurance/Quality Control	company ensures the highest quality across all products through a rigorous quality control mechanism at every stage of the manufacturing process.				
Experienced Promoters & Management Team	Influx is led by Mr. Munir A. Chandniwala and Ms. Shirin Munir Ahmed Chandniwala, with a shared vision for growth, quality, and patient-centric care, further strengthened by Mr. Abdul Ganee Chandniwala's expertise.				



PROCEEDS FROM OUR IPO WILL BE STRATEGICALLY DEPLOYED TO:

Enhance Manufacturing Infrastructure: Increasing production capacity across all divisions Expand R&D Capabilities: Developing future-ready formulations in nutraceuticals, cosmetics, pet care, and homecare Strengthen Global Market Reach: Targeting new geographies and expanding private-label offerings Boost Digital & Direct-To-Consumer (D2c) Capabilities: Aligning with evolving consumer trends.



Tapping The Public Markets - Eyeing Listing



OBJECTS OF THE ISSUE

Sr.No.	Particulars Particulars	Estimated Amount (Rs. Lakh)
1	Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division	2,249.11
2	Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division	1,148.58
3	Purchase of Machineries for Homecare and Cosmetic Division	275.65
4	General Corporate Expenses	[•]
	Total	[•]



Details Of The Issue



Fresh Issue	50,00,400 Equity Shares
OFS Size	11,00,400 Equity Shares
Total Issue Size	61,00,800 Equity Shares
Issue Type	Fresh Issue & Offer for Sale
Anchor Book Opens	17th June 2025
Issue Opens	18th June 2025
Issue Closes	20th June 2025
Anchor Book	17,36,400 Equity Shares
Reserve for Market Maker	3,06,000 Equity Shares
QIBs	28,95,600 Equity Shares
Retail	20,29,200 Equity Shares
Lot Size	1200 Equity Shares
Book Running Lead Manager	RarEver Financial Advisors Private Limited
Registrar	Maashitla Securities Private Limited

Rar Ever Financial Advisors Private Limited

RareEver Financial Advisors Private Limited are a distinguished Merchant Banking and boutique Investment Banking Firm that specializes in guiding large and mid-sized corporations through the intricate world of financial growth and capital acquisition. The firm is dedicated to providing comprehensive financial advisory services, including Valuations, Private Equity, ESOPs, SME IPOs, Main Board IPOs, Rights Issues, Buy Backs and Preferential Issues, among other merchant banking-related activities.



Peer Group Comparison



Sr. No.	Name of Company	Face Value (Rs.)	Total Revenue (Rs. Cr.)	PAT (In Rs. Crs.)	EPS (Rs.)	Market Cap	P/E Ratio	RoNW (%)	NAV per Share (Rs.)
1	Influx Healthtech Limited	10	104.99	13.37	7.36	[•]	[•]	36.98	19.91
	Peer Group as Per RHP								
2	Sudarshan Pharma Industries Limited	1	505.38	15.88	0.66	766.50Crs	48.28	12.45	5.30
3	Quest Laboratories Limited	10	108.16	13.57	8.28	140.77	10.38	16.58	49.92

Prominent Industry Player*

Sr. No.	Name of Company	Face Value (Rs.)	Total Revenue (Rs. Cr.)	PAT (In Rs. Crs.)	EPS (Rs.)	Market Cap	P/E Ratio	RoNW (%)	NAV per Share (Rs.)
4	Akums Drugs & Pharmaceuticals Ltd.	2	1311.78	161.00	10.2	9089 Crs	56.5	13.2	146.8

^{*}For Industry understanding and information purpose only, not part of RHP







INFLUX HEALTHTECH LTD.

Reg. Office: 109, Ghanshyam Enclave, New Link Road, Behind Laljipada Police Chowky, Kandivali(W), Mumbai, Maharashtra, India – 400067

Contact : +91 80803 33319 / +91 9082232942

Email: info@influxhealthtech.com • Web.: www.influxhealthtech.com